Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The global diagnostics supplier said the multi-phase expansion aims to deliver more than 60 commercially available recombinant antigen products by 2030
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
Subscribe To Our Newsletter & Stay Updated
